PLUS1
79.67
-2.99 (-3.62%)
-2.99 (-3.62%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Emergent Biosolutions Inc | EBS | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -2.99 | -3.62% | 79.67 | 18:43:39 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 82.87 | 77.73 | 83.7699 | 79.67 | 82.66 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 10,166 | 690,440 | $ 80.26 | $ 55,414,546 | 646,003 | 46.37 - 137.61 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:00:00 | 36,916 | $ 79.67 | USD |
Emergent Biosolutions Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 4.22B | 53.00M | 51.02M | $ 1.11B | $ 140.12M | 1.03 | 26.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Emergent Biosolutions News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/12/2020 | 18:30 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/06/2020 | 06:07 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 11/05/2020 | 16:44 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/05/2020 | 16:05 | GlobeNewswire Inc. | Emergent BioSolutions Reports Financial Results for Third.. |
| 10/15/2020 | 06:30 | GlobeNewswire Inc. | Emergent BioSolutions to Release Third Quarter 2020.. |
| 10/08/2020 | 16:05 | GlobeNewswire Inc. | Emergent BioSolutions’ COVID-19 Human Immune Globulin.. |
| 10/05/2020 | 17:29 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EBS Price Data
| Period †| Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 87.00 | 88.80 | 77.73 | 83.17 | 556,240 | -7.33 | -8.43% |
| 1 Month | 96.00 | 99.83 | 77.73 | 89.03 | 541,321 | -16.33 | -17.01% |
| 3 Months | 117.48 | 118.00 | 77.73 | 98.16 | 600,039 | -37.81 | -32.18% |
| 6 Months | 86.00 | 137.61 | 64.50 | 97.29 | 773,362 | -6.33 | -7.36% |
| 1 Year | 51.86 | 137.61 | 46.37 | 85.05 | 609,911 | 27.81 | 53.63% |
| 3 Years | 40.85 | 137.61 | 39.11 | 67.96 | 439,687 | 38.82 | 95.03% |
| 5 Years | 37.50 | 137.61 | 24.47 | 55.34 | 416,341 | 42.17 | 112.45% |
Emergent Biosolutions Description
| Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products. |
